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ApoptosisDefensins are cationic antimicrobial peptides that play an important role in innate immunity by primarily
acting against microbes. Their antimicrobial properties have been widely studied and are well under-
stood. Defensins contribute to regulation of host immunity also. Their effects on cells of the host however
are less well understood. Here, we report on the pro-inﬂammatory and apoptotic properties of Human
Defensin 5, the major antimicrobial peptide of ileal Paneth cells. We ﬁnd that HD-5 up-regulates expres-
sion of genes involved in cell survival and inﬂammation in a NF-kB-dependent fashion in epithelial cells.
Further, we ﬁnd that HD-5 has pro-apoptotic effects on intestinal epithelial cells as well as primary CD4+
T cells.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Human defensins are cationic peptides of the innate immune
system with the ability to kill a variety of microbial pathogens,
including bacteria, fungi and viruses [1,2]. Based on a difference
in disulﬁde connectivity of six conserved cysteine residues, defen-
sins have been divided in two families, termed a and b. Both fam-
ilies are believed to have evolved from a common ancestral b-
defensin gene [3,4], and share similar tertiary structures despite
low amino acid sequence identity [5–7].
In addition to their antimicrobial activities, defensins play a sig-
niﬁcant role in adaptive and innate immunity. Defensins have been
shown to chemoattract a variety of host cells [8–10] and have
shown the ability to modulate host cell cytokine responses
[11,12]. Defensins of the a-family are expressed predominantly
in neutrophils (termed human neutrophil peptides or HNP) or in
specialized intestinal epithelial cells called Paneth cells in the case
of Human Defensin 5 and 6 (HD-5 and HD-6) [13,14]. Recently, a
speciﬁc deﬁciency of HD-5 was observed in patients with ileal Cro-
hn’s disease, a chronic inﬂammatory disease [15,16]. These ﬁnd-
ings have led to the notion that HD-5 as an innate immune
effector molecule may play an important role in the maintenance
of mucosal balance and that deﬁciency of HD-5, resulting in weak-
ening of mucosal antibacterial capacity may contribute to patho-
genesis [17]. Although the antibacterial properties of HD-5 have
been described [18,19], little is known about immunomodulatoryproperties of the peptide on host cells. Here, we describe the
immunomodulatory properties of HD-5.
2. Materials and methods
2.1. Solid phase peptide synthesis
Chemical synthesis of HD-5 and HD-5Abu, a linear, unstructured
form of HD-5 in which the six cysteine residues are replaced by
isosteric a-aminobutyric acid (Abu) was carried out as described
[20]. The molecular mass of the peptides was veriﬁed by electro-
spray ionization mass spectrometry (ESI-MS) as described [20].
2.2. Cell culture
Subconﬂuent monolayers of Caco-2 cells were maintained in
RPMI 1640 medium (Gibco), supplemented with 10% FBS (Valley
Biomedical, Winchester, VA), 2 mM L-glutamine (Quality Biologi-
cal, Gaithersburg, MD), 20 mM HEPES, 1 nonessential amino
acids, 1 mM sodium pyruvate and 5% Penicillin/Streptomycin (Sig-
ma) in a humidiﬁed incubator at 37 C with 5% CO2. Caco-2 cells
were used between passages 18–35 and were plated at a density
of 4  105 cells/cm2.
2.3. Reverse transcriptase-polymerase chain reaction (RT-PCR) and
gene expression analysis
Caco-2 cells were cultured in 12-well plates in the presence of
serum. Cells were gently washed twice with serum-free medium
and incubated for a further 6 h in serum-free medium containing
the peptide5 at a ﬁnal concentration of 50 lg/ml. Total RNA was
extracted and transcribed into cDNA using the FastLane Cell cDNA
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expression analysis was subsequently carried out using Signal
Transduction Pathway Finder PCR arrays from SABiosciences
according to manufacturer’s protocol. Data were evaluated using
the DDCt method and gene expression fold upregulation was plot-
ted according to instructions on the company website.
2.4. Evaluation of cytokine secretion
Caco-2 cells were cultured in 96-well plates in the presence of
serum. Cells were gently washed twice with serum-free medium
and incubated for a further 24 h in serum-free medium containing
the peptides at indicated concentrations. To study the role NF-kB in
signal transduction, cells were pre-incubated for 2 h in the pres-
ence of 50 lg/ml M-132 (Sigma). CD4+ T cells were puriﬁed from
PHA-activated peripheral blood monocytes obtained from healthy
volunteer donors of the New York Blood Bank. Following activa-
tion, CD-4+ T cells were isolated by negative selection according
to the manufacturer’s instructions (Mylteni Biotec), washed in
serum-free medium and exposed to peptide at 25 lg/ml for 4 h.
Culture supernatants were collected for measurement of IL-8 using
the Luminex-100 system (Bio-Rad).
2.5. Cell viability
The effect of defensin peptides on Caco-2 cell viability was as-
sessed by measuring the mitochondrial activity using MTS assays
according to the manufacturer’s instructions (Cell Titer 96 prolifer-
ation assay, Promega). The cells were gently washed twice with ser-
um-free medium and incubated for a further 24 h in serum-free
medium containing the peptides at a ﬁnal concentration of 20, 50
or 100 lg/ml. The number of viable cells was determined using a
standard curveof seriallydiluteduntreatedcells in eachexperiment.
2.6. Apoptotic assays
Caspase-3/-7 activity in Caco-2 cell lysates was measured using
the ﬂuorogenic Ac-DEVD-AMC peptide substrate. Cells were gentlyFig. 1. Upregulation of gene expression by Caco-2 cells treated with HD-5 (50 lg/ml) for
Human Signal Transduction Pathway Finder PCR array (SABiosciences) and data were an
compared to control after 6 h or more than 8-fold upregulation for 16 h are listed. Transcr
Transcription Factor2; BCL2A1: B-cell Lymphoma2-related protein A1; BIRC2/BIRC3: Bac
Cyclin-dependent kinase inhibitor A1; CYP19A1: Cytochrome P450; FAS:TNF receptor s
MatrixMetalloProtease; PTGS2: Prostaglandin-endoperoxidase synthase 2; SELE: Selecti
Adhesion Molecule-1; WNT2: Wingless-type MMTV integration site family member 2.washed twice with serum-free medium and exposed to the pep-
tides at a ﬁnal concentration of 20, 50 or 100 lg/ml. The general
caspase inhibitor zVAD was incubated for 2 h before exposure of
the cells to HD-5 at 50 lM. Cells were lysed in 200 ll of lysis buffer
(20 mM HEPES, 50 mM NaCl, pH 7.2, 10 mM DTT containing 1%
CHAPS, 1 mM EDTA, 2 mM PMSF, leupeptin (10 lg/ml; Sigma)
and pepstatin A (10 lg/ml; Sigma) for 30 min on ice. After centri-
fugation (7000g, 10 min), protein concentration was determined
using the BCA Protein assay reagent (Bio-Rad). Subsequently,
20 lg of each sample was diluted to a ﬁnal volume of 200 ml in as-
say buffer (20 mM HEPES, 50 mM NaCl, pH 7.2, 10 mM DTT, 0.1%
CHAPS containing 100 mM Ac-DEVD-AMC) in a 96-well plate.
Fluorescence was determined (excitation 360 nm, emission
460 nm) with a Cary Eclipse ﬂuorescence spectrophotometer (Var-
ian, Palo Alto, CA). Background ﬂuorescence was determined using
the assay buffer only.
Apoptosis in puriﬁed CD4+ T cells was determined using the An-
nexin-FITC apoptosis kit from Calbiochem according to manufac-
turer protocol. Puriﬁed CD4+ T cells (2  105 cells/ml) were
exposed to peptide in serum-free medium and subsequently ana-
lyzed by ﬂow cytometry (FACSCalibur, BD Biosciences).3. Results
3.1. Interaction of HD-5 with cells of the host
To study the functional effects of the HD-5 peptide on host cells,
Caco-2 intestinal epithelial cells were exposed to the peptide at a
concentration of 50 lg/ml for 6 or 16 h and the differential gene
expression was compared to untreated control cells (Fig. 1). HD-5
induced the expression by more than 15-fold after 6 h or 8-fold
after 16 h of three major groups of genes in Caco-2 cells: (1) regu-
lation of cell survival (BCL2A1, BIRC2, BIRC3, FAS, TANK, TNF); (2)
pro-inﬂammatory (IL-2, IL-8, CCL-20, TNFa); (3) cell adhesion
(MMP7, MMP10, SELE, VCAM1). Notably, transcription of 50% of
the genes induced by HD-5 is NF-jB-dependent. Pre-incubation
of Caco-2 cells with the broad NF-jB neutralizing agent M-1326 h or 16 h versus control untreated cells. Expression was determined by RT2 Proﬁle
alyzed using the DDCt method. Only genes with a more than 15-fold upregulation
iption of genes marked in green is NF-kB-dependent. Abbreviations: ATF2: Activating
uloviral IAP Repeat Containing; CCL20: Chemokine (C-C motif) Ligand 20; CDKN1A:
uperfamily member 6; IL: InterLeukin; KLK2: Kallikrein-related peptidase 2; MMP:
n E; TANK:Traf family member associated NF-kB Activator; VCAM1: Vascular Cell
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Fig. 2. Induction of IL-8 secretion by HD-5 is NF-jB-dependent. Caco-2 cells were
preincubated with the NF-jB inhibitor M-132. Subsequently, Caco-2 cells were
exposed to HD-5 peptides at 50 lg/ml for 24 h in serum-free medium. Protein
secretion was determined by ELISA; means ± SEM from three independent exper-
iments for HD-5 are shown.
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RT-PCR experiments (Fig. 2).
We previously observed that IL-8 secretion diminished at high-
er HD-5 concentrations and at longer exposure times. Given that
HD-5 affects expression of cell survival genes after 6 h, we tested
for cytotoxic effects of the HD-5 peptides by measuring metabolic
activity using the MTS assay (Fig. 3A). Incubation of the cells with
HD-5 for 24 h at a concentration of 50 lg/ml resulted in a 20% de-
creased mitochondrial activity and by more than 60% at a concen-
tration of 100 lg/ml. No decreased activity was observed for a
linear HD-5 Abu peptide, in which the six cysteine residues have
been replaced by butyric acid. Incubation of the cells with peptide
for 6 h did not noticeably alter cell viability. Since Caco-2 cell via-
bility was affected by HD-5, we examined the possibility that HD-5
induces programmed cell death. Apoptotic cell death is character-
ized by activation of caspases, including caspase-3/-7. Therefore,
caspase-3/-7 activity in cellular lysates was determined after expo-
sure to the peptides at a concentration of 50 lg/ml for 6 h or 24 h.HD-5
HD-5 Abu
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Fig. 3. Pro-apoptotic effects of HD-5. (A) Caco-2 cells were exposed to the peptides at co
activity was measured by MTS colorimetric measurement and plotted as percentage of u
50 lg/ml for 6 or 24 h in serum-free medium. Caspase-3/-7 activity in cellular substrates w
was inhibited by pre-incubation of the cells with the broad caspase inhibitor zVAD
reorganization induced by HD-5. Caco-2 cells were exposed to HD-5 at a concentration o
was visualized by phalloidin staining using Hoechst counterstaining to visualize cellulaActivity was determined by measuring ﬂuorescence of AMC after
cleavage of the DEVD peptide substrate (Fig. 3B). After 6 h, no sig-
niﬁcant caspase-3/-7 activity was detected for any of the peptides
as compared to untreated cells. After 24 h, caspase activity was sig-
niﬁcantly increased in cells treated with HD-5. The broad-spec-
trum caspase inhibitor zVAD was able to abrogate this HD-5
induced caspase activity. We determined the effect of HD-5 on
cytoskeletal reorganization as a second measure for apoptosis
since we found that HD-5 induces expression of cell adhesion
genes as well as activates caspase enzymes. Compared to control
cells, HD-5 induces a dramatic disruption of the actin cytoskeleton.
Concentration-dependent secretion of IL-8 as well as disruption of
the actin cytoskeleton and decreased cell viability was observed
also upon exposure of HD-5 to Jurkat cells (not shown). Taken to-
gether, these data suggest that HD-5 can mediate NF-jB-depen-
dent signaling at low concentrations and negatively affects host
cell viability through caspase activation at higher concentrations
or prolonged exposure.
We used puriﬁed CD4 T cells to examine the effects of HD-5 on
primary cells, rather than cell lines. Puriﬁed CD4+ T cells were ex-
posed to increasing concentrations of HD-5 in serum-free medium
and assayed for cytokine release by ELISA and apoptosis by ﬂow
cytometry. As expected, HD-5 induced secretion of IL-8 and IL-2
by these cells, in accordance with our RT-PCR results (Fig. 4A).
Additionally, exposure to HD-5 induced secretion of interferon-
gamma (Fig. 4A). No secretion of IL-4, IL-1b or TNFa could be ob-
served by these cells following exposure to the peptide. Prolonged
exposure of the peptide induced predominantly apoptotic events
even at concentrations of HD-5 as low as 5 lg/ml. At this concen-
tration, approximately 50% of the cell population was undergoing
early or late stage apoptotic events (Fig. 4B). At increased peptide
concentrations, the percentage of cells undergoing late stage apop-
totic events or necrotic events increased 8- to 10-fold compared to6 hours
24 hours
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Fig. 4. HD-5 induces interleukin secretion and apoptosis on CD4+ T cells. (A) Puriﬁed CD4+ T cells derived from PHA-activated peripheral blood monocytes were exposed to
HD-5 at 25 lg/ml for 4 h. Interleukins in the supernatant were detected by ELISA using the Luminex assay from Invitrogen. Means ± SEM for one of two independent
experiments carried out in triplicate is shown. (B) HD-5 was exposed to puriﬁed CD4+ T cells derived from PHA-activated peripheral blood monocytes at the indicated
concentrations for 6 h and assayed for apoptotic events by ﬂow cytometry. One out of three representative experiments is shown.
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primary CD4+ T cells. Linearized HD-5 was unable to induce either
cytokine release or apoptosis.4. Discussion
Several recent studies have shown abnormally low expression
levels of HD-5 patients suffering from Crohn’s disease. Diminished
HD-5 levels have been linked to two independent underlying sig-
naling pathways. First, mutations in NOD2/CARD15 gene encoding
an intracellular receptor for the bacterial peptidoglycan compo-
nent muramyl dipeptide have been linked with susceptibility to
Crohn’s disease [21,22]. Second, defensin deﬁciency has been
linked to the Wnt/b-catenin/Tcf-4 pathway, independent from
the NOD2/CARD15 genotype [16]. These observations have led to
the suggestion that decreased levels of a-defensin secreted by Pa-
neth cells located at the base of small intestinal crypts weaken the
antimicrobial defense of the ileal mucosa [23]. Indeed, HD-5 deﬁ-
ciency in man alters the bacterial composition of the gut [15].
Transgenic overexpression of HD-5 in mice protects against oral
challenge with Salmonella [24] and alters the gut microbiome also
[25]. Interestingly, HD-5 transgenic mice show a striking loss of
segmented ﬁlamentous bacteria and have fewer IL-17-producing
lamina propria T cells [25]. Loss of IL-17-producing T cells however
was also observed in wild-type mice with functional defensins, in
the speciﬁc absence of this class of bacteria. Our studies suggest
a concentration-dependent effect of defensins. In the healthy intes-tine, HD-5 is continuously secreted at low levels. The concentration
of HD-5 in ileal ﬂuid has been quantiﬁed to range between 6–
30 lg/ml [26]. Concentrations of pro-HD-5 stored in granules of
Paneth cells has been estimated between 90 and 450 lg/cm2 of
ileal surface area, translating roughly into 50–250 lg/ml upon
complete degranulation and processing [18]. At these concentra-
tions, we predict that the antibacterial activity of defensins would
be minimal, due to presence of salts and cations in intestinal ﬂuid,
known to inhibit its antibacterial activity [27]. We ﬁnd here that at
low or steady-state concentrations, HD-5 has pro-inﬂammatory
properties. In healthy individuals, these properties are likely bene-
ﬁcial in maintaining epithelial integrity and regulating controlled
inﬁltration of immune cells into underlying tissues. In a recent
study describing allograft rejection of intestinal tissue, which clo-
sely resembles Crohn’s disease, it was noted that decrease in epi-
thelial antimicrobial peptides preceded visible epithelial injury
[28]. One of the earliest visible signs of epithelial damage in this
study was increased apoptosis of the epithelium. Furthermore, re-
duced alpha-defensin expression was recently found to be associ-
ated with inﬂammation but not with NOD2 mutations [29]. The
observed inﬂammatory changes resulted in loss of epithelium, sug-
gesting that lower expression of alpha-defensins is a consequence
of ileal inﬂammation in Crohn’s disease.
Barrier integrity of the mucosa is generally believed to be regu-
lated by signaling of key regulator cytokines to cells of the adaptive
immune system. A contrasting view is offered in several studies
with epithelial-speciﬁc deletions of crucial regulators of signaling
pathways. For example, speciﬁc deletion of NEMO, a master regu-
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neous colitis in mice [30]. Impaired NF-jB led to epithelial apopto-
sis, translocation of bacteria into the mucosa and reduced
expression of defensins. Epithelial-speciﬁc deletion of RelA, a sub-
unit of NF-jB causes spontaneous intestinal disease and death [31].
Deletion of RelA elevated basal rates of epithelial apoptosis and
proliferation and was accompanied by diminished expression of
anti-apoptotic genes and defensins. More recently, intestinal epi-
thelial-speciﬁc deletion of MyD88, a key regulator of Toll-like
receptor mediated signaling [32], was found to cause spontaneous
colitis in aged mice. Disease was characterized by increased bacte-
rial translocation and decreased defensin expression [33]. Surpris-
ingly, epithelial apoptosis or permeability was not found to be
increased. Although not conﬁrmed in man, degranulation of mur-
ine Paneth cells from isolated crypts by LPS or other stimuli results
in estimated defensin concentrations as high as 20 mg/ml in the
crypt lumen [34]. Our studies indicate that at these concentrations,
defensins not only kill micro-organisms instantly, but induce
strong pro-inﬂammatory and pro-apoptotic effects as well. Based
on the above and on our ﬁndings, we suggest that defensin deﬁ-
ciency affects both the gut microbiome and host immunity and
may contribute to disease development and progression, likely
however only in combination with genetic or environmental fac-
tors. Treatment or prevention of disease with HD-5 as a therapeu-
tic agent may be beneﬁcial, however may accelerate the
development or be harmful in cases of active disease.
Various studies have indicated speciﬁc interactions between
defensins and host cell receptors. Both a- and b-defensins have
been shown to act chemotactic to a variety of cells, including naïve
and mature T cells, mast cells and macrophages [9], immature den-
dritic cells [35] and monocytes [36]. Members of the b-defensin
family have been shown to interact with a variety of cellular recep-
tors, including the chemokine receptor CCR6 [8,37], Toll-Like
Receptor 4 [38] and more recently the melanocortin 1 receptor
[39], causing black coat color in domestic dogs. Defensins share
striking common characteristics with chemokines, such as size,
cationic charge, disulﬁde bonding and biological activities
[40,41]. Predominantly based on the ability of defensins to act as
chemoattractants, it was concluded that a-defensins may share a
common receptor, distinct from b-defensins [9,10]. The only mem-
ber of the a-defensin family with reported receptor interactions is
Human Neutrophil Peptide-1 or HNP-1. Interaction of HNP-1 with
the purinergic receptor PY2 on airway epithelial cells has been re-
ported [42]. More recently however, the activation of macrophages
by HNP-1 was shown to be insensitive to pertussis toxin, as well as
independent of purinergic receptors, Toll-like Receptor and CD18
signaling [43]. In agreement with the above mentioned studies,
we showed that signaling in Caco-2 cells is relatively insensitive
to pertussis toxin treatment [27]. Further, pre-incubation with
the PY2-receptor speciﬁc antagonist suramin did not alter the IL-
8 secretion induced by HD-5 in Caco-2 cells, suggesting that this
pathway is not involved (unpublished observation). Previously, it
was suggested that a-defensins chemoattract cells via a unique
receptor, predominantly involving p38 and ERK pathways [9].
Our previous studies and this work indicate that HD-5 signals with
similar pathway speciﬁcity [27,44] and activates NF-jB (this work).
To date, no speciﬁc receptors for HD-5 have been identiﬁed.Acknowledgments
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